CompletedNot Applicable

A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product

United States16 participantsStarted 2007-06

Plain-language summary

This protocol intends to detail investigations necessary to evaluate the ocular safety of subjects enrolled in study A4321001 and who have received formulated Drug Product (Lot 8716-098).

Who can participate

Age range55 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A subset of subjects enrolled in study A4321001 and who have received formulated drug product (Lot 8716-098) will be included in the safety follow up study. Exclusion Criteria: None

What they're measuring

follow up for ocular safety and clinical features of ocular siderosis

Timeframe: 12 months

Trial details

NCT IDNCT00471224

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2008-11

View on ClinicalTrials.gov More Siderosis trials